Our founders, Professor Moein Moghimi and Dr. Shadi Farhangrazi outline in an invited Nature Index perspective the need for sustained investment of novel platforms like SMDG's proprietary technology platforms and new frameworks to transforming therapies for children with rare diseases. July 2026